Yoplait, Go-Gurt Are Up for Ingredient Review, Lactalis Says
Top dairymaker Lactalis says it will assess ingredients in newly-acquired yogurt brands like Yoplait and Go-Gurt as Health Secretary Robert F. Kennedy Jr.'s 'Make America Healthy Movement' campaigns for changes in the US food supply, including reducing sugar and removing artificial ingredients.
The company, which completed its acquisition of General Mills's US yogurt business on Monday, will start discussions on ingredients within the next 30 days, said Lactalis US Yogurt Chief Executive Officer Bill Cassidy. The deal was first announced last September.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
4 hours ago
- Bloomberg
Yoplait, Go-Gurt Are Up for Ingredient Review, Lactalis Says
Top dairymaker Lactalis says it will assess ingredients in newly-acquired yogurt brands like Yoplait and Go-Gurt as Health Secretary Robert F. Kennedy Jr.'s 'Make America Healthy Movement' campaigns for changes in the US food supply, including reducing sugar and removing artificial ingredients. The company, which completed its acquisition of General Mills's US yogurt business on Monday, will start discussions on ingredients within the next 30 days, said Lactalis US Yogurt Chief Executive Officer Bill Cassidy. The deal was first announced last September.
CNBC
8 hours ago
- CNBC
Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and the company's separate combination flu and Covid jab. Moderna in May voluntarily withdrew an application seeking approval of its combination shot targeting Covid-19 and influenza, saying it had plans to resubmit it with efficacy data from the phase three trial on its standalone flu vaccine. That decision came after discussions with the Food and Drug Administration, which is grappling with a massive overhaul under Health and Human Services Secretary Robert F. Kennedy Jr., a prominent vaccine skeptic. With the new data, the company plans to resubmit the application for the combination vaccine and file for approval of its standalone flu shot later this year, Stephen Hoge, the company's head of research and development, said in an interview. If regulators approve the flu vaccine, the company can then advance the combination shot, Hoge said. He added that Moderna expects approvals for both shots next year pending reviews. He said the combination jab simplifies vaccination, which will "help the health-care system" by reducing workloads of doctors and nurses, slashing costs and improving uptake among patients. The company so far appears to be the frontrunner in the race against Pfizer and Novavax to bring a combination shot to the market. While Moderna does not have specific revenue projections for its individual products, Hoge said Covid, flu and respiratory syncytial virus are each multi-billion-dollar markets. "We're obviously hoping that our products allow us to earn our fair share of them," he said. The phase three trial followed more than 40,000 adults ages 50 and above, who were randomly assigned to receive a single dose of Moderna's shot, called mRNA-1010, or a standard competitor vaccine. Moderna's shot was 26.6% more effective than the other vaccine in the overall study population. The mRNA-1010 jab also demonstrated strong efficacy for each of the major influenza strains in the shot, including A/H1N1, A/H3N2 and the B/Victoria lineages. Moderna said the vaccine's benefit was consistent across different age groups, people with various risk factors and previous vaccination status against the flu. In adults ages 65 and older, the shot was 27.4% more effective than the standard flu vaccine. The efficacy results are "a significant milestone in our effort to reduce the burden of influenza in older adults," Moderna CEO Stephane Bancel said in a release. "The severity of this past flu season underscores the need for more effective vaccines." Moderna cited data from the Centers for Disease Control and Prevention showing that seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024 to 2025 season of the virus. More than 600,000 Americans were hospitalized due to flu-related illness last year, according to the CDC. The mRNA-1010 vaccine's safety data was consistent with previous results from another phase three study on the shot. Shares of Moderna are down more than 30% for the year, fueled in large part by a string of moves by the Trump administration to change vaccine policy and undermine immunizations. The administration in May canceled a contract awarded to Moderna for the late-stage development of its bird flu vaccine for humans. When asked about the uncertain regulatory environment in the U.S., Hoge said Moderna is engaging closely with the FDA to understand what its requirements are and how to satisfy them. "I believe, as relates to flu, I think we've got a pretty clear path," he said.
Axios
10 hours ago
- Axios
New docs get schooled in old diseases as vax rates fall
Rush University Medical Center in Chicago is adding a new twist to its curriculum for medical students and residents, using AI tools and learning modules to teach how to more quickly identify measles rashes on different skin tones. Why it matters: It's another reminder that diseases once thought to have been eradicated are showing up with increased frequency in clinics and ERs, posing challenges for younger physicians and health workers who thought they were relegated to history. Lingering vaccine hesitancy and distrust of the medical establishment stoked by Health Secretary Robert F. Kennedy Jr. are leading some health systems to add training on old scourges that were practically wiped out by immunization campaigns and increased surveillance. "You're taught these things in medical school, and you're taught from a very academic perspective with the sense of measles was eradicated in 2000," said Nicholas Cozzi, EMS medical director at Rush. "Now we're having a resurgence, the highest in 25 years, and you might have not reviewed that since the first year of medical school," he added. "It's a new paradigm and a new normal that we have to adapt to." The big picture: The focus is particularly acute on childhood illnesses such as measles, chicken pox, invasive strep pneumoniae and pertussis, experts told Axios. Polio and diphtheria, covered by the DTap vaccine, are also a concern. An unvaccinated 10-year-old boy died in Germany after contracting diphtheria, once the leading cause of premature death of children. Rubella — a less easily transmitted infection covered by the MMR vaccine — can also be a threat, because of the way it can infect a fetus during pregnancy, said Catherine Troisi, professor at UTHealth Houston School of Public Health and chair-elect of the International Network of Epidemiology in Policy. Vaccination rates for U.S. kindergartners were down slightly in 2023-24 for the DTap, polio, chickenpox and MMR shots, according to CDC data. Zoom in: Paul Offit, director of the Vaccine Education Center at Children's Hospital of Philadelphia, said rotavirus is another old disease that's being introduced to younger doctors. "That virus dominated my residency [in the 1970s]. We had 400 kids admitted every winter," Offit said. That was before a vaccine was licensed in 2006 and virtually eliminated 70,000 hospitalizations with severe diarrhea annually, he added. "Now it's the rare child who ever gets admitted. Most pediatric residents have never seen a case of rotavirus-induced dehydration in the hospital," he said. Between the lines: Incidents such as the measles outbreak in Texas and Kennedy's recent changes to federal vaccine policy are heightening vigilance and forcing updates to physician training. It will likely take time for medical schools and residency programs to formally change their training, Troisi pointed out. Medical professionals are being advised to stay current on public health advisories, ask patients about travel histories and be on guard for less likely conditions that may present as more common ailments. They may also have to brush up on best practices for spinal taps in infants and toddlers, an invasive diagnostic tool that is seldom used today but can quickly turn up telltale signs such as inflamed membranes, said Adrianna Cadilla, a pediatric infectious diseases specialist at Nemours Children's Health in Orlando. "When I trained, I would hear my attendings tell us about how often they had to do lumbar punctures because that was when Hemophilus influenza type B was running rampant," Cadilla said. "I only got to do probably one every ER shift, but that was a lot in comparison to now." The hospital is using simulations to get medical students and residents more experienced in doing spinal tap on infants and wriggling older children, she said. What to watch: New outbreaks could force more on-the-fly adjustments, especially in areas with low vaccination rates and the prospect of fewer recommended childhood immunizations.
